Printer Friendly

ADRIA ANNOUNCES FINALIZATION OF MYCOBUTIN CO-PROMOTION AGREEMENT

 DUBLIN, Ohio, July 9 /PRNewswire/ -- Adria Laboratories announced that it has completed an agreement with SmithKline Beecham to co-promote Adria's recently approved prescription drug MYCOBUTIN(TM) (rifabutin capsules).
 MYCOBUTIN is the only drug approved for the prevention of Mycobacterium Avium Complex (MAC), a life-threatening bacterial infection common in people with advanced HIV disease.
 This agreement calls for the SmithKline Beecham hospital sales force of 230 people to join in the promotion efforts for MYCOBUTIN in cooperation with the Adria sales force of 139.
 "The finalization of the agreement with SmithKline Beecham is gratifying. Their sales organization is widely recognized in the industry as very professional and highly successful. As a result, we expect to improve our ability to educate the physician community and people with AIDS about MAC disease and the importance of prevention," stated Fernando da Costa, president of the Kabi Pharmacia/Farmitalia Carlo Erba U.S. organization of which Adria Laboratories is a part.
 Adria Laboratories, based in Dublin, Ohio is a recognized leader in oncology drug research and development.
 -0- 7/9/93
 /CONTACT: Bethany Beck of Adria Laboratories, 614-764-8162/


CO: Adria Laboratories; SmithKline Beecham ST: Ohio IN: MTC SU:

MP-LR -- NY035 -- 9910 07/09/93 12:26 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 9, 1993
Words:202
Previous Article:DUKE POWER $75 MILLION MEDIUM-TERM NOTES DUE 2003 'AA' BY FITCH -- FITCH FINANCIAL WIRE --
Next Article:MAGNA GROUP ANNOUNCES AGREEMENT TO ACQUIRE CITY BANCORP, INC.; FIVE LOCATIONS TO COMPLEMENT MAGNA COMMUNITY BANK NETWORK
Topics:


Related Articles
COCENSYS ANNOUNCES MANAGEMENT ADDITIONS AND PROMOTIONS
ADRIA LABORATORIES REPRESENTATIVES AVAILABLE FOR COMMENT
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MYCOBUTIN(TM) FOR THE PREVENTION OF AIDS-RELATED INFECTION
FDA APPROVES RIFABUTIN FOR PREVENTION OF MAC DISEASE
ADRIA LABORATORIES AND SMITHKLINE BEECHAM AGREE TO CO-PROMOTE MYCOBUTIN
PHS TASK FORCE RECOMMENDS PROPHYLAXIS AGAINST AIDS-RELATED INFECTION WITH MYCOBUTIN
MYCOBUTIN PREVENTS ONSET OF AIDS-RELATED INFECTION
FEDERAL TASK FORCE ANNOUNCES PREVENTION AND TREATMENT RECOMMENDATIONS FOR AIDS-RELATED INFECTION
PHARMACIA INC. ANNOUNCES CLINICAL TRIALS FOR TUBERCULOSIS PREVENTION; STUDY TO TARGET PEOPLE WITH HIV AND THE UNDERSERVED

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters